OGM analysis was performed on a specific CD34 + CD19-CD22+ early cell population present at diagnosis of B-ALL patients and probably responsible for relapse after CD19-targeted immunotherapy. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.